HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
Stereotaxis (NYSE: STXS) announced that HonorHealth has launched a robotic electrophysiology program at its Scottsdale Shea Medical Center, utilizing the Genesis Robotic Magnetic Navigation (RMN) system. This initiative aims to enhance patient care for those undergoing cardiac ablation procedures, vital for treating arrhythmias. Dr. Rahul Doshi emphasized the program's potential to transform care, while Dr. Maulik Shah highlighted HonorHealth's commitment to advanced medical technologies. David Fischel, CEO of Stereotaxis, expressed enthusiasm about supporting HonorHealth's vision in improving patient outcomes.
- HonorHealth's adoption of Stereotaxis' robotic technology indicates a growing acceptance of innovative medical solutions.
- The launch of the robotic electrophysiology program may lead to increased demand for Stereotaxis' systems, potentially boosting revenue.
- None.
ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona. HonorHealth is among the first in the nation to offer the Genesis Robotic Magnetic Navigation (RMN) system to patients receiving minimally invasive cardiac ablation procedures.
“Establishing a robotic electrophysiology program allows us to offer improved care for patients, furthering our guiding vision to build a preeminent Cardiovascular Center of Excellence at HonorHealth,” said Dr. Rahul Doshi, chief of complex arrhythmia management. “I have closely followed the evolution of technologies in our field and am excited by the promise of robotics to positively transform electrophysiology for patients, physicians and health systems.”
Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“Adopting this robotic system reflects HonorHealth’s commitment to providing patients the most advanced technologies and treatment options,” said Dr. Maulik Shah, executive director of the HonorHealth Destination Center of Excellence and cardiovascular service line. “Countless individuals in Scottsdale and the greater Phoenix region are affected by irregular heartbeats. HonorHealth continues to invest in addressing the unmet medical needs in our community.”
“We are delighted to work with HonorHealth” said David Fischel, chairman and CEO of Stereotaxis. “We applaud their leadership and look forward to supporting their efforts to improve patient care, advance clinical science, and build a preeminent heart rhythm program.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
FAQ
What is the significance of HonorHealth's robotic electrophysiology program for STXS?
When was the robotic electrophysiology program at HonorHealth announced?
How does the Genesis RMN system relate to Stereotaxis?
What are the expected benefits of the robotic system for cardiac procedures?
How many patients have benefited from Stereotaxis technology globally?
